Ovid Therapeutics appoints Dr Jerome B. Zeldis to Its Scientific Advisory Board
pharmafile | October 9, 2015 | Appointment | Medical Communications |
Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, has announced the appointment to its Scientific Advisory Board (SAB) of Jerome B. Zeldis, MD, PhD, chief executive officer of Celgene Global Health and chief medical officer of Celgene Corporation.
Dr Zeldis is noted for his exceptional and successful experience in drug development. Prior to his current role at Celgene, Dr Zeldis served as Celgene’s senior vice president of Clinical Research and Medical Affairs.
Prior to joining Celgene in 1997, Dr Zeldis was associate director of clinical research at Sandoz Research Institute where he helped develop Zelnorm (tegaserod) and director of medical development at Janssen Pharmaceutical Research Institute where he worked on Prepulsid (cisapride).
He currently serves as chairman of the board of Semorex Corporation and has additional board positions at Alliqua, Bionor Pharma, PTC Therapeutics, Soligenix, and Trek Therapeutics. He was assistant professor of medicine at Harvard Medical School, associate professor of medicine at University of California, Davis, clinical associate professor of medicine at Cornell Medical School, and professor of clinical medicine at the Robert Wood Johnson Medical School.
Dr Zeldis received BA and MS degrees from Brown University, and M Phil, MD, and PhD degrees from Yale University.
“We are delighted and privileged to welcome Jerry to our Scientific Advisory Board,” said Dr Jeremy Levin, chief executive officer and chairman of Ovid. “Jerry’s advice and insight will be extremely valuable as we enter the clinic.”
Dr Zeldis comment: “Ovid is pursuing an ambitious approach of tackling rare neurological diseases with significant unmet needs. With this goal, the company has assembled a world-class leadership and is employing a science-based approach to target new pathways that are involved in these diseases. I look forward to working closely with Ovid’s team.”
